108736-35-2
108736-35-2
Chemical Structure
Lanreotide
Synonym(s): BIM 23014
- CAS No.: 108736-35-2
- Formula:C54H69N11O10S2
- Molecular Weight:1096.32
InChIKey: PUDHBTGHUJUUFI-SCTWWAJVSA-N
SMILES: O=C([C@@H](NC([C@@](CSSC[C@@H](C(N[C@H](C(N)=O)[C@H](O)C)=O)NC([C@H](C(C)C)NC([C@@](CCCCN)([H])NC1=O)=O)=O)([H])NC([C@H](N)CC2=CC3=CC=CC=C3C=C2)=O)=O)CC4=CC=C(O)C=C4)N[C@@H]1CC5=CNC6=C5C=CC=C6
Biological Activity: Lanreotide (BIM 23014) is a somatostatin analogue with antineoplastic activity. Lanreotide can be used for the research of carcinoid syndrome[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Lanreotide | 98.86% | Lanreotide (BIM 23014) is a somatostatin analogue with antineoplastic activity. Lanreotide can be used for the research of carcinoid syndrome. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Ning S, et al. Lanreotide promotes apoptosis and is not radioprotective in GH3 cells.Endocr Relat Cancer. 2009 Sep;16(3):1045-55. [Content Brief]
- [2]. Florio T, et al. Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro.Clin Endocrinol (Oxf). 2003 Jul;59(1):115-28. [Content Brief]
